Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer Presented ByDr Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA TrialLIBRETTO-001 ConferenceWCLC 2019 8 November, 2019 19:01
